BALLERUP, Denmark - Saturday, 17. September 2022 AETOSWire
Positive CHMP opinion recommends extending use of Adtralza® (tralokinumab) to adolescents (12-17 years old) in the European Union (EU)
Recommendation supported by data from the Phase 3 ECZTRA 6 trial
(BUSINESS WIRE) -- LEO Pharma…